BIOVECTRA signs service agreement with Acuitas Therapeutics for unique lipid nanoparticle (LNP) delivery system used in manufacturing mRNA-based therapies

BIOVECTRA and Acuitas Therapeutics, Inc. today announced that they have entered into a technology transfer service.

Novel drug holds promise for treating Duchenne muscular dystrophy

A novel drug holds promise for treating Duchenne muscular dystrophy (DMD), a rare genetic disorder that causes severe muscle degeneration.

December 16, 2024

Investors optimistic about continued biotech and medtech IPO resurgence in 2025 – Pharmaceutical Technology

Despite numerous challenges faced by life sciences this year, IPOs have emerged as a resilient force. Image credit: GettyImages/ Daniel Grill. When Australian biotech Telix

December 23, 2024

Opinion | ‘Not Game-Over for COVID’: What We Heard This Week

“It’s not game-over for COVID.” — Farida Ahmad, MPH, of the CDC’s Division of Vital Statistics at the National Center for Health Statistics in Maryland,

August 12, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.